Should I buy or sell Codexis stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks .

What is Codexis' stock price target for 2024?

6 Wall Street research analysts have issued 1-year target prices for Codexis' stock. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $6.80 in the next year. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts .

How have CDXS shares performed in 2024?

Codexis' stock was trading at $3.05 on January 1st, 2024. Since then, CDXS shares have decreased by 8.2% and is now trading at $2.80. View the best growth stocks for 2024 here .

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CDXS earnings forecast .

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.18. The biotechnology company had revenue of $26.56 million for the quarter, compared to analysts' expectations of $24.73 million. Codexis had a negative net margin of 108.69% and a negative trailing twelve-month return on equity of 47.58%.

What ETF holds Codexis' stock?

Jacob Forward ETF holds 11,844 shares of CDXS stock, representing 1.17% of its portfolio.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.0 million-$64.0 million, compared to the consensus revenue estimate of $58.9 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com . John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , Micron Technology (MU) , Enphase Energy (ENPH) , Intellia Therapeutics (NTLA) , NVIDIA (NVDA) , OPKO Health (OPK) and Antares Pharma (ATRS) .

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

→ Your Next Portfolio Star: Revealing 2024's Top Stock Pick (From Darwin) (Ad)

Free CDXS Stock Alerts

$2.80

+0.04 (+1.45%)

(As of 04:35 PM ET)

Compare

Today's Range: $2.71
▼
$2.88
50-Day Range: $2.69
▼
$4.65
52-Week Range: $1.45
▼
$4.91

Volume: 615,947 shs
Average Volume: 573,547 shs
Market Capitalization: $196.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.80

Get Codexis alerts:

Codexis MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 142.9% Upside
$6.80 Price Target
Short Interest: Bearish
3.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -3.67
Upright™ Environmental Score
News Sentiment: 0.20
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.60) to ($0.63) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.76 out of 5 stars

Medical Sector

399th out of 919 stocks

Industrial Organic Chemicals Industry

11th out of 18 stocks

3.3

Analyst's Opinion

Consensus Rating
Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Codexis has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.39% of the outstanding shares of Codexis have been sold short.
Short Interest Ratio / Days to Cover
Codexis has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Codexis has recently increased by 3.93%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Codexis does not currently pay a dividend.
Dividend Growth
Codexis does not have a long track record of dividend growth.

2.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Codexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Codexis is -3.67.

1.2

News and Social Media Coverage

News Sentiment
Codexis has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Codexis this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Codexis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Codexis is held by insiders.
Percentage Held by Institutions
78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Codexis are expected to decrease in the coming year, from ($0.60) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Codexis is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Codexis is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Codexis has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About Codexis Stock (NASDAQ:CDXS)

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDXS Stock News Headlines

April 18, 2024 | globenewswire.com

Codexis to Report First Quarter 2024 Financial Results on May 2

April 15, 2024 | americanbankingnews.com

Financial Review: Codexis (NASDAQ:CDXS) & Golden Arrow Merger (NASDAQ:GAMC)

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 11, 2024 | globenewswire.com

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

April 10, 2024 | americanbankingnews.com

Codexis (NASDAQ:CDXS) Share Price Crosses Above Two Hundred Day Moving Average of $2.65

March 30, 2024 | finance.yahoo.com

Favourable Signals For Codexis: Numerous Insiders Acquired Stock

March 19, 2024 | seekingalpha.com

AQST,CDXS and STI are among after hour movers

March 1, 2024 | msn.com

Benchmark raises Codexis to buy; cites Q4 earnings, guidance

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

March 1, 2024 | msn.com

Benchmark Upgrades Codexis (CDXS)

February 29, 2024 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS)

February 29, 2024 | finance.yahoo.com

Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript

February 29, 2024 | finanznachrichten.de

Codexis, Inc.: Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 29, 2024 | finance.yahoo.com

Q4 2023 Codexis Inc Earnings Call

February 28, 2024 | benzinga.com

Recap: Codexis Q4 Earnings

February 28, 2024 | msn.com

Codexis GAAP EPS of -$0.10 beats by $0.04, revenue of $26.56M beats by $7.63M

February 28, 2024 | finance.yahoo.com

Codexis Inc (CDXS) Reports Fiscal Year 2023 Financial Results

February 28, 2024 | globenewswire.com

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 28, 2024 | theglobeandmail.com

Biotech Rallied Strongly On Exclusive Licensing Agreement

February 27, 2024 | marketwatch.com

Codexis Shares Up 31% on Roche Licensing Agreement

February 27, 2024 | msn.com

Codexis Q4 2023 Earnings Preview

February 26, 2024 | msn.com

Codexis stock climbs 11% on Roche licensing deal for DNA ligases

February 26, 2024 | globenewswire.com

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

February 26, 2024 | globenewswire.com

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

February 20, 2024 | finance.yahoo.com

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

February 20, 2024 | globenewswire.com

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

February 16, 2024 | money.usnews.com

Codexis Inc.

See More Headlines

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Industrial organic chemicals
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CDXS
CUSIP: 19200510
CIK: 1200375
Web: www.codexis.com
Phone: (650) 421-8100
Fax: 650-421-8102
Employees: 174
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.80
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +150.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,240,000.00
Net Margins: -108.69%
Pretax Margin: -108.59%
Return on Equity: -47.58%
Return on Assets: -28.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.61
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: $70.14 million
Price / Sales: 2.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.24 per share
Price / Book: 2.19

Miscellaneous

Outstanding Shares: 70,300,000
Free Float: 65,875,000
Market Cap: $191.22 million
Optionable: Optionable
Beta: 2.01

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Stephen George Dilly MBBS (Age 64)
Ph.D., President, CEO & Director
Comp: $753.61k
Mr. Kevin Norrett M.B.A. (Age 51)
M.S., Chief Operating Officer
Comp: $507.28k
Ms. Margaret Fitzgerald J.D. (Age 53)
Chief Legal and Compliance Officer, General Counsel & Secretary
Comp: $300.03k
Mr. Sriram Ryali M.B.A. (Age 42)
Chief Financial Officer
Carrie McKim
Director of Investor Relations
Ms. Karen Frechou-Armijo
Senior VP & Head of Human Resources
Dr. Stefan Lutz Ph.D.
Senior Vice President of Research
Mr. Robert Sato M.B.A.
Ph.D., Senior Vice President of Pharmaceutical Development, Quality & Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Codexis stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.
What is Codexis' stock price target for 2024?: 6 Wall Street research analysts have issued 1-year target prices for Codexis' stock. Their CDXS share price targets range from $4.00 to $10.00. On average, they predict the company's share price to reach $6.80 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.
How have CDXS shares performed in 2024?: Codexis' stock was trading at $3.05 on January 1st, 2024. Since then, CDXS shares have decreased by 8.2% and is now trading at $2.80.
View the best growth stocks for 2024 here.
When is Codexis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CDXS earnings forecast.
How were Codexis' earnings last quarter?: Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.18. The biotechnology company had revenue of $26.56 million for the quarter, compared to analysts' expectations of $24.73 million. Codexis had a negative net margin of 108.69% and a negative trailing twelve-month return on equity of 47.58%.
What ETF holds Codexis' stock?: Jacob Forward ETF holds 11,844 shares of CDXS stock, representing 1.17% of its portfolio.

What guidance has Codexis issued on next quarter's earnings?: Codexis issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.0 million-$64.0 million, compared to the consensus revenue estimate of $58.9 million.
What is John J. Nicols' approval rating as Codexis' CEO?: 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.
What other stocks do shareholders of Codexis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).
How do I buy shares of Codexis?: Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDXS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial